Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company pioneering new approaches to develop innovative drug combinations that target serious orphan and common neurodegenerative diseases. The company's disruptive NextCure platform simultaneously identifies and develops multiple synergistic drug combinations, called Pleodrugs, with the potential to offer improved efficacy and safety profiles. Pharnext's lead Pleodrug, PXT3003, is currently in late-stage clinical development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare genetic neurological disorder. The company is dedicated to transforming the treatment of neurodegenerative diseases by delivering innovative therapeutic solutions to patients with unmet medical needs.